Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature
| Autor: | Diocesio Alves Pinto de Andrade, Andre Deeke Sasse, Joao Lima, Lucas Vieira dos Santos, Alan Duarte Lima |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Bevacizumab Organoplatinum Compounds Colorectal cancer medicine.medical_treatment Leucovorin Antibodies Monoclonal Humanized Carcinoembryonic antigen Embryonic antigen Antigen Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Biomarkers Tumor Humans Pharmacology (medical) neoplasms Pharmacology Chemotherapy biology business.industry Middle Aged medicine.disease digestive system diseases Carcinoembryonic Antigen Regimen Treatment Outcome Fluorouracil biology.protein business Colorectal Neoplasms medicine.drug |
| Zdroj: | Anti-cancer drugs. 22 |
| ISSN: | 1473-5741 |
| Popis: | Bevacizumab-containing treatment is one of the approved first-line options for the management of metastatic colorectal cancer (CRC). Carcino-embryonic antigen (CEA) is a reasonable tumour marker for monitoring the efficacy of treatment. We report here a case of a 58-year-old male patient with metastatic CRC. He received first-line chemotherapy consisting of the mFOLFOX6 regimen plus bevacizumab. Initially he had an increase in CEA after which the level reduced, suggesting the occurrence of a CEA flare. The patient experienced a good response to therapy. In recent literature, CEA flare was identified as a good predictor of response to first-line chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|